Zobrazeno 1 - 10
of 381
pro vyhledávání: ''
Autor:
Momal Chand, Valentina Hoyos, Jason A Mouabbi, Daniel Ockner, Mothaffar F. Rimawi, Amr Aref, Tarik Hadid, Ramen Sakhi, Carrie L. Dul, Ishaq A. Asghar
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4790-4795 (2021)
Cancer Medicine
Cancer Medicine
Objective The goal was to compare the 5‐year DFS and 5‐year OS in patients with early‐stage human epidermal growth factor receptor 2 breast cancer (HER2+ BC) and triple‐negative breast cancer (TNBC) in relation to the amount of stromal tumor
Autor:
Ilaria Portarena, Gianluca Vanni, Stefano Rizza, Tommaso Perretta, Marco Pellicciaro, Chiara Adriana Pistolese, Oreste Claudio Buonomo, Domiziana Pedini, Chiara Buonomo, Marco Materazzo
Publikováno v:
Anticancer Research. 41:2689-2696
BACKGROUND/AIM: The COVID-19 lockdown includes restrictive measures and temporary health system reorganization. Resources were shifted to COVID-19 patients, screening programs were temporary suspended, and oncological care suffered slow-down. The aim
Publikováno v:
Anticancer Research. 41:187-195
Background Amplification of chromosome 8q with locus 8q24 is the most common copy number aberration, and is associated with tumour progression and chemoresistance. Materials and methods The study used paired samples of biopsy and surgical material fr
Autor:
Jiangzhou Zhang, Shuheng Bai, Xingzhou Zhang, Yanli Yan, Haojing Kang, Guangzu Li, Zhaode Feng, Wen Ma, Hong Sun, Juan Ren
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment
Objective: To compare the effects of 2 techniques of semi-hepatic alternating radiotherapy on diffuse hepatic metastasis in patients with breast cancer. Methodology: A total of 68 breast cancer patients with diffuse liver metastasis were randomly div
Autor:
Manabu Futamura, Takashi Ishikawa, Yoshihisa Tokumaru, Lan Le, Kazuaki Takabe, Mariko Asaoka, Kazuhiro Yoshida
Publikováno v:
Translational cancer research
An antibody-drug conjugate targeting HER2, DS8201, has shown clinical activity against breast cancer with low-level HER2 expression. We aimed to evaluate the prognostic impact of intermediate HER2 expression in estrogen receptor (ER)+ early breast ca
Autor:
Simonetta Bianchi, Irene Renda, Milo Giani, Tommaso Susini, Ketty Tavella, A. Villanucci, Ermanno Vanzi, Arianna Vallario, Jacopo Nori
Publikováno v:
Anticancer Research. 40:1079-1085
Background/aim We evaluated the efficacy of neoadjuvant chemotherapy (NACT) in reducing locally-advanced breast cancer (LABC) size, thus improving breast-conserving surgery (BCS) rates, as well as its long-term outcome. Patients and methods We analyz
Autor:
E. Shelley Hwang, Terry Hyslop, Rachel A. Greenup, Jennifer K. Plichta, Rebecca Vernon, Oluwadamilola M. Fayanju, Samantha M. Thomas, Laura H. Rosenberger
Publikováno v:
Breast Cancer Res Treat
BACKGROUND: Given presumed differences in disease severity between young (≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extre
Autor:
Arjen J. Witkamp, M. Sier, Wiesje Maarse, M.L. Gregorowitsch, C. H. van Gils, T. van Dalen, H.J.G.D. Van den Bongard, A. Doeksen, Helena M. Verkooijen, Marilot C T Batenburg, A. Braakenburg, Danny A. Young-Afat, E J P Schoenmaeckers
Publikováno v:
Breast Cancer Research and Treatment
Purpose To evaluate patient-reported cosmetic satisfaction in women treated with radiation therapy for breast cancer and to determine the association between dissatisfaction and quality of life (QoL) and depression. Methods Within the prospective UMB
Autor:
Bo Bae Choi
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment
Background: Neoadjuvant chemotherapy (NAC) is known to be a suitable treatment and first-line defense for locally advanced breast cancer. However, the NAC response may include unexpected outcomes, and it is not easy to predict the NAC response precis
Publikováno v:
Breast Cancer Research and Treatment. 178:401-408
Agents targeting the human epidermal growth factor receptor 2 (HER2) have improved outcomes of advanced HER2-positive breast cancer with durable responses. We evaluated first-line therapy long-term outcomes in patients responding for more than 1 year